Super Bowl advertising has always been about pushing boundaries, capturing attention, and setting new creative standards. But this year, the risk-taking was noticeably dialled down.
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.